Twist Bioscience Corp
TWST28.460USD
-5.220-15.50%
Market hours （ET）Quotes delayed by 15 min
1.70BMarket Cap
LossP/E TTM
More Details of Twist Bioscience Corp Company
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
Company Info
Ticker SymbolTWST
Company nameTwist Bioscience Corp
IPO dateOct 31, 2018
CEODr. Emily M. Leproust, Ph.D.
Number of employees923
Security typeOrdinary Share
Fiscal year-endOct 31
Address681 Gateway Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone18007190671
Websitehttps://www.twistbioscience.com/
Ticker SymbolTWST
IPO dateOct 31, 2018
CEODr. Emily M. Leproust, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
341.19K
-0.14%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
113.61K
-2.10%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
50.03K
-0.25%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
47.07K
-0.30%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
12.60K
+55.04%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
8.25K
-22.88%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
341.19K
-0.14%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
113.61K
-2.10%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
50.03K
-0.25%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
47.07K
-0.30%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
NGS tools
51.15M
55.12%
Synthetic genes
28.22M
30.41%
Antibody discovery
5.70M
6.14%
Oligo pools
4.71M
5.08%
DNA libraries
3.02M
3.25%
By RegionUSD
Name
Revenue
Proportion
Americas
55.19M
59.48%
EMEA
30.64M
33.02%
APAC
6.96M
7.50%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
NGS tools
51.15M
55.12%
Synthetic genes
28.22M
30.41%
Antibody discovery
5.70M
6.14%
Oligo pools
4.71M
5.08%
DNA libraries
3.02M
3.25%
Shareholding Stats
Updated: Tue, May 20
Updated: Tue, May 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.68%
The Vanguard Group, Inc.
9.77%
Artisan Partners Limited Partnership
9.77%
BlackRock Institutional Trust Company, N.A.
7.73%
William Blair Investment Management, LLC
6.52%
Other
55.53%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.68%
The Vanguard Group, Inc.
9.77%
Artisan Partners Limited Partnership
9.77%
BlackRock Institutional Trust Company, N.A.
7.73%
William Blair Investment Management, LLC
6.52%
Other
55.53%
Shareholder Types
Shareholders
Proportion
Investment Advisor
61.44%
Investment Advisor/Hedge Fund
39.92%
Hedge Fund
8.43%
Research Firm
3.10%
Individual Investor
1.97%
Pension Fund
1.40%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.27%
Family Office
0.24%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
574
70.28M
117.29%
-746.72K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
2023Q1
593
64.77M
113.93%
-4.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
6.24M
10.42%
-140.57K
-2.20%
Mar 31, 2025
The Vanguard Group, Inc.
5.85M
9.77%
+60.28K
+1.04%
Mar 31, 2025
Artisan Partners Limited Partnership
5.85M
9.77%
-42.31K
-0.72%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.63M
7.73%
+9.40K
+0.20%
Mar 31, 2025
William Blair Investment Management, LLC
3.81M
6.35%
+857.14K
+29.06%
Mar 31, 2025
Invesco Advisers, Inc.
3.34M
5.57%
-197.51K
-5.59%
Mar 31, 2025
State Street Global Advisors (US)
2.69M
4.5%
+149.68K
+5.88%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
2.42M
4.03%
-197.17K
-7.55%
Mar 31, 2025
Thrivent Asset Management, LLC
1.51M
2.51%
+532.04K
+54.64%
Dec 31, 2024
Point72 Asset Management, L.P.
1.43M
2.39%
+1.43M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
7.54%
iShares Genomics Immunology and Healthcare ETF
4.75%
Global X Genomics & Biotechnology ETF
2.67%
WisdomTree BioRevolution Fund
2.24%
ARK Innovation ETF
2.09%
Franklin Genomic Advancements ETF
1.79%
ROBO Global Healthcare Technology & Innovation ETF
1.75%
BNY Mellon Innovators ETF
0.77%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.73%
SPDR S&P Biotech ETF
0.7%
View more
ARK Genomic Revolution ETF
Proportion7.54%
iShares Genomics Immunology and Healthcare ETF
Proportion4.75%
Global X Genomics & Biotechnology ETF
Proportion2.67%
WisdomTree BioRevolution Fund
Proportion2.24%
ARK Innovation ETF
Proportion2.09%
Franklin Genomic Advancements ETF
Proportion1.79%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.75%
BNY Mellon Innovators ETF
Proportion0.77%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.73%
SPDR S&P Biotech ETF
Proportion0.7%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
